Biotech Archives - Page 680 of 795

2 minute read

Journal Of Precision Medicine Publication Confirms GeneType Risk Test Outperforms Traditional Risk Assessments For Breast Cancer

September 29, 8:19 AM

MELBOURNE, Australia, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited ((ASX: GTG, NASDAQ:GENE, "Company", "GTG")), a global leader in genomics-based tests in health, wellness and

GENE

1 minute read

VBI Vaccines Announces Initiation Of Phase 1 Study Of Multivalent Coronavirus Vaccine Candidate, VBI-2901

By Benzinga Newsdesk

September 29, 8:09 AM

Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses Preclinical data support broadly reactive immunity of VBI-2901 against

VBIV

1 minute read

Biohaven Provides Update From Pivotal Phase 2/3 Trial With Verdiperstat In Amyotrophic Lateral Sclerosis

By Benzinga Newsdesk

September 29, 8:01 AM

Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) today announced results from a focused analysis of treatment with verdiperstat in the HEALEY ALS Platform Trial in amyotrophic lateral sclerosis (ALS). The HEALEY

BHVN

1 minute read

InflaRx Submits Request For Emergency Use Authorization To US FDA For Vilobelimab For Treatment Of Critically Ill COVID-19 Patients

By Benzinga Newsdesk

September 29, 7:35 AM

Company also earns FDA Fast Track designation for vilobelimab to treat critically ill COVID-19 patients EUA submission based on Phase III results in critically ill COVID-19 patients, recently published in The

IFRX

1 minute read

Atara Biotherapeutics to Receive Additional Near-Term Milestone Under Updated Tab-cel Commercialization Pact

By Vandana Singh

September 29, 7:30 AM

Atara Biotherapeutics Inc (NASDAQ:ATRA) announced an update to its existing collaboration agreement with Pierre Fabre for the commercialization of tabelecleucel (tab-cel) for Epstein-Barr…

ATRA

1 minute read

Axsome Therapeutics Announces Plans To Resubmit AXS-07 NDA Based On Successful FDA Type A Meeting; No Additional Clinical Efficacy Or Safety Trials Have Been Requested By The FDA For A Resubmission Of The NDA

By Benzinga Newsdesk

September 29, 7:12 AM

- Reuters

AXSM

1 minute read

Gilead’s Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme

By Vandana Singh

September 29, 7:10 AM

U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead Sciences Inc's (NASDAQ: GILD) HIV drugs.

GILD

2 minute read

EyePoint Pharmaceuticals Announces First Patient Dosed In Phase 2 PAVIA Clinical Trial Of EYP-1901 For The Treatment Of Non-Proliferative Diabetic Retinopathy

By Benzinga Newsdesk

September 29, 7:08 AM

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that the first

EYPT

1 minute read

Novo Nordisk Enters License Deal With Ventus Therapeutics To Develop Drugs To Treat Inflammatory Diseases

By Benzinga Newsdesk

September 29, 6:42 AM

- Reuters

NVO

1 minute read

Axcella Announces Interim Data From Phase 2b EMMPACT Study Of AXA1125 In Nonalcoholic Steatohepatitis

By Benzinga Newsdesk

September 29, 6:06 AM

Subjects enrolled with biopsy confirmed NASH experienced clinically and statistically significant improvements in liver stiffness as measured by FibroScan, a non-invasive measure of liver fibrosis Subjects with

AXLA